Aller au contenu principal
Accès ouvert déclaré2024preprint

CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming

0Citations signalées
5Institutions associées
3Pays d’affiliation

Résumé fourni par la source

Abstract Colorectal cancer (CRC) progression is shaped by the tumor microenvironment, particularly tumor-associated macrophages (TAMs), which often adopt immunosuppressive functions. CD300e, a myeloid receptor involved in immune regulation, has an uncharacterized role in CRC. Here, we show that CD300e is selectively upregulated in tumor-infiltrating monocytes and macrophages, driving a suppressive phenotype marked by impaired antigen presentation. In vitro cocultures of patient-derived tumor organoids and human monocytes revealed that tumor-derived signals induce CD300e expression and promote a protumorigenic macrophage profile. Using CD300e knockout mice in AOM/DSS and MC38 CRC models, we found that CD300e loss reduced tumor burden, enhanced MHC expression on TAMs, and improved T-cell responses. Transcriptomic and functional analyses demonstrated that CD300e-deficient macrophages exhibit increased phagocytosis, upregulated antigen presentation, and greater support for T-cell proliferation and cytotoxicity. Adoptive transfer confirmed that macrophage-intrinsic CD300e expression is sufficient to suppress T-cell function and promote tumor growth. Our findings identify CD300e as a critical regulator of macrophage-mediated immune suppression in CRC and a potential target for reprogramming TAMs to enhance immunotherapy.

Institutions

Sujets associés

Immune Cell Function and InteractionCancer Immunotherapy and BiomarkersImmune cells in cancer

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.